August 7, 2019
While reporting a “narrow miss” for its closely watched trial for Entresto (sacubitril + valsartan), Novartis submitted the global blockbuster heart failure drug in Japan late last month for “chronic heart failure” without specifying its subtypes. The drug could gain...read more